CA1033362A - Process for the preparation of acethydroxamic pyrimidin-6-yl acids - Google Patents
Process for the preparation of acethydroxamic pyrimidin-6-yl acidsInfo
- Publication number
- CA1033362A CA1033362A CA222,169A CA222169A CA1033362A CA 1033362 A CA1033362 A CA 1033362A CA 222169 A CA222169 A CA 222169A CA 1033362 A CA1033362 A CA 1033362A
- Authority
- CA
- Canada
- Prior art keywords
- par
- formule
- radical
- dans
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims abstract description 4
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims description 8
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- -1 pyrrolidino, piperidino Chemical group 0.000 abstract description 3
- 208000001953 Hypotension Diseases 0.000 abstract description 2
- 208000021822 hypotensive Diseases 0.000 abstract description 2
- 230000001077 hypotensive effect Effects 0.000 abstract description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- BQIKRTGTPBOIMK-UHFFFAOYSA-N [O]C[O] Chemical compound [O]C[O] BQIKRTGTPBOIMK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 239000002269 analeptic agent Substances 0.000 abstract 1
- 230000003555 analeptic effect Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000767 anti-ulcer Effects 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 230000002276 neurotropic effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 230000000304 vasodilatating effect Effects 0.000 abstract 1
- 230000003416 augmentation Effects 0.000 description 9
- 206010002660 Anoxia Diseases 0.000 description 6
- 241000699729 Muridae Species 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7409235A FR2264529A2 (en) | 1973-04-16 | 1974-03-19 | Substd. pyrimidin-6-yl acethydroxamic acids - useful as vasodilators, anti-ulcer agents etc. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1033362A true CA1033362A (en) | 1978-06-20 |
Family
ID=9136513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA222,169A Expired CA1033362A (en) | 1974-03-19 | 1975-03-14 | Process for the preparation of acethydroxamic pyrimidin-6-yl acids |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4013768A (enExample) |
| JP (1) | JPS50126681A (enExample) |
| BE (1) | BE826017R (enExample) |
| CA (1) | CA1033362A (enExample) |
| CH (1) | CH567001A5 (enExample) |
| DE (1) | DE2510026A1 (enExample) |
| ES (1) | ES435406A2 (enExample) |
| GB (1) | GB1438099A (enExample) |
| IT (1) | IT1044486B (enExample) |
| LU (1) | LU71929A1 (enExample) |
| NL (1) | NL7503227A (enExample) |
| SE (1) | SE7503058L (enExample) |
| SU (1) | SU530643A3 (enExample) |
| ZA (1) | ZA751560B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4061855A (en) * | 1974-03-19 | 1977-12-06 | Delalande S.A. | Pyrimidin-6-yl acethydroxamic acids |
| WO1997039750A1 (en) * | 1996-04-19 | 1997-10-30 | The Regents Of The University Of California | Treatment of mood/affective disorders by glutamatergic upmodulators |
| WO1999037293A2 (en) * | 1998-01-27 | 1999-07-29 | Thomas Thomas N | Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders |
| CA2391952C (en) | 1999-11-23 | 2012-01-31 | Methylgene Inc. | Inhibitors of histone deacetylase |
| BRPI0817433A2 (pt) * | 2007-10-19 | 2015-06-16 | Janssen Pharmaceutica Nv | Moduladores de gama-secretase piperidinila e piperazinila |
| AU2008312355B2 (en) * | 2007-10-19 | 2013-07-04 | Janssen Pharmaceutica, N.V. | Carbon linked modulators of y-secretase |
| EA018862B1 (ru) * | 2007-10-19 | 2013-11-29 | Янссен Фармацевтика, Н.В. | МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ |
| US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790287A (fr) * | 1971-10-28 | 1973-04-19 | Delalande Sa | Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique |
-
1975
- 1975-02-26 BE BE153774A patent/BE826017R/xx active
- 1975-02-27 LU LU71929A patent/LU71929A1/xx unknown
- 1975-03-03 CH CH264975A patent/CH567001A5/xx not_active IP Right Cessation
- 1975-03-03 US US05/554,532 patent/US4013768A/en not_active Expired - Lifetime
- 1975-03-04 GB GB882975A patent/GB1438099A/en not_active Expired
- 1975-03-07 ES ES435406A patent/ES435406A2/es not_active Expired
- 1975-03-07 DE DE19752510026 patent/DE2510026A1/de active Pending
- 1975-03-13 ZA ZA00751560A patent/ZA751560B/xx unknown
- 1975-03-14 CA CA222,169A patent/CA1033362A/en not_active Expired
- 1975-03-17 JP JP50031269A patent/JPS50126681A/ja active Pending
- 1975-03-18 SU SU2115291A patent/SU530643A3/ru active
- 1975-03-18 NL NL7503227A patent/NL7503227A/xx active Search and Examination
- 1975-03-18 IT IT67680/75A patent/IT1044486B/it active
- 1975-03-18 SE SE7503058A patent/SE7503058L/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU7882175A (en) | 1976-09-09 |
| JPS50126681A (en) | 1975-10-04 |
| GB1438099A (en) | 1976-06-03 |
| ES435406A2 (es) | 1977-03-01 |
| BE826017R (fr) | 1975-08-26 |
| NL7503227A (nl) | 1975-09-23 |
| SU530643A3 (ru) | 1976-09-30 |
| IT1044486B (it) | 1980-03-20 |
| DE2510026A1 (de) | 1975-09-25 |
| CH567001A5 (enExample) | 1975-09-30 |
| LU71929A1 (enExample) | 1975-12-09 |
| SE7503058L (enExample) | 1975-09-22 |
| ZA751560B (en) | 1976-02-25 |
| US4013768A (en) | 1977-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6354321A (ja) | 血糖降下剤 | |
| EP0605622B1 (en) | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs | |
| US6110952A (en) | 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists | |
| US4423056A (en) | 5(Aminomethyl)-4,5,6,7-tetrahydro[d]thiazole containing compositions for and medical use in treating circulatory insufficiencies | |
| EP0063509A1 (fr) | Nouveaux dérivés de pipérazino-2 pyrimidine, procédés pour leur préparation, médicaments les contenant et leur utilisation comme intermédiaires pour la fabrication de médicaments | |
| FR2654621A1 (fr) | Inhibition du syndrome d'abstinence. | |
| FR2631827A1 (fr) | Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique | |
| EP0074873B1 (fr) | Dérivés de phénoxy-3 propanol-2, leur préparation et leur application en thérapeutique | |
| CA2000247A1 (fr) | Derives de methyl-4 ¬(phenyl-4 piperazinyl-1)-2 ethyl -5| thiazole, leur procede de preparation et les compositions pharmaceutiques, en contenant | |
| LU81554A1 (de) | Alkylthiophenoxyalkylamines | |
| LU79970A1 (fr) | Procede de preparation de derives de 1-phenyl-1-propanol | |
| AU729421B2 (en) | Guinidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists | |
| LU84315A1 (fr) | Spirothiazolidinedione,son procede de production et preparation pharmaceutique la contenant | |
| EP0647221A1 (fr) | Aryl-1 (o-alcoxyphenyl-4 piperazinyl-1)-2, -3 ou -4 alcanols, leur procede de preparation et leur utilisation pour la preparation de medicaments | |
| CA2272644A1 (en) | 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists | |
| EP0100257B1 (fr) | Nouveaux dérivés aminoalkyl naphtaléniques, leurs sels d'addition d'acide et le procédé de préparation ainsi que l'application en thérapeutique de ces dérivés et sels | |
| CA2074833A1 (fr) | Derives d'(alkylthio-3 propyl)-3 benzothiazoline, leur preparation et les medicaments les contenant | |
| EP0409692A2 (fr) | Dérivés d'imino-2 hétérocyclylalkyl-3 benzothiazoline, leur préparation et les médicaments les contenant | |
| EP0577470A1 (fr) | Dérivés de 2-amino-N-[[[4-(aminocarbonyl)pyrimidin-2-yl]-amino]alkyl]pyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique | |
| CA1252465A (fr) | Derives (alcoxy-2) phenylpiperaziniques, leur methode de preparation et leur application therapeutique | |
| EP0625514B1 (fr) | Dérivés de 2-aminopyrazine-5-carboxamide, leur préparation et leur application en thérapeutique | |
| FR2568878A1 (fr) | Nouveaux derives de (phenylpiperazinylethylamine ethoxy)-4 phenol, leur methode de preparation et leur application therapeutique | |
| KR840001967B1 (ko) | 1,1,3,5-치환 뷰렛 화합물의 제조방법 | |
| EP0226475A1 (fr) | Nouveaux dérivés de la diphénoxyethylamine, leur procédé d'obtention et les compositions pharmaceutiques en renfermant | |
| FR2581643A1 (fr) | Compositions pharmaceutiques utiles dans le domaine de l'urologie, contenant de l'acetoxy-1 methyl-2 ((piperidino)-2 ethoxy)-4 (methyl-1 ethyl)-5 benzene ou l'un de ses sels |